Anti-CD20 (Rituximab), Chimeric Antibody

CATALOG NO: A1049-100

ALTERNATE NAMES: MabThera

AMOUNT: 100 µg

IMMUNOGEN: CD20

HOST: Human/Mouse Chimeric

ISOTYPE: Human IgG1

CLONALITY: Monoclonal

SOURCE: Mammalian (murine myeloma) cell culture

ENDOTOXIN LEVELS: < 0.05 EU/ml

PURIFICATION: Protein A

SPECIES REACTIVITY: Human

FORM: Liquid

FORMULATION: Supplied in phosphate buffered saline, pH 7.4

STORAGE CONDITIONS: For long term storage, it's recommended to keep at -20°C. Once thawed, keep it at 4°C. Prepare working dilution prior to use. Avoid repeated freezing and thawing

SPECIFICITY: Rituximab (bio-similar) is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kDa. Rituximab (bio-similar) is produced in mammalian (murine myeloma) cell culture.

DESCRIPTION: Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and antibody dependent cellular cytotoxicity. Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies.

APPLICATION: Neutralization: 0.1-20 µg/ml, ELISA: 2 µg/ml

Note: This information is only intended as a guide. The optimal dilutions must be determined by the user.

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (Cat. No. A1045-100)
- Anti-EGFR (Cetuximab), chimeric antibody (Cat. No. A1047-100)
- Anti-TNF-α (Adalimumab), humanized antibody (Cat. No. A1048-100)
- Anti-HER2 (Trastuzumab), humanized Antibody (Cat. No. A1046-100)
- Anti-EGFR (Panitumumab), humanized antibody (Cat. No. A1050-100)
- HER2, Active, Human Recombinant (Cat. No. 8011-5)
- HER2, Active (Cat. No. 7762-5)
- HER2/ErbB2 Antibody (Cat. No. 3783-100)